Chunk #66 — 5. Procedures for evaluating pharmacological treatments targeting alcohol abuse and dependence — 5.7. Relapse of ethanol drinking in the operant chamber

Source

Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Embedded

yes

Text

been shown that LY404039, an mGluR2/3 agonist (Rodd et al., 2006), and SB-334867, an orexin1 receptor antagonist (Dhaher et al., 2010), reduce ethanol-seeking and relapse-like (i.e., ADE) operant ethanol responding, respectively, by P rats. In another study with P rats, MPEP, an mGluR5 antagonist, reduced both the maintenance of operant ethanol responding as well as the expression of an operant ADE (Schroeder et al., 2005a).